Robert H. Weiss, M.S., M.D.

Clinical Interests

Robert H. Weiss' clinical interests include the diagnosis and treatment of all renal diseases and electrolyte problems. His research interests concern the cyclins and cyclin inhibitors, cancer growth control (kidney and breast cancer), metabolomics and proteomics, and polycystic kidney disease.

Title

Professor Emeritus

Specialty

Nephrology

Department

Internal Medicine

Division

Nephrology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Additional Phone

Phone: 800-4-UCDAVIS (800-482-3284)
Phone: 530-752-4010

Email

rhweiss@ucdavis.edu

Education

M.D., UC Irvine College of Medicine, Irvine CA 1984
M.S., Physical Chemistry, UCLA, Los Angeles CA 1978
M.S., Medical Physics, UCLA, Los Angeles CA 1980
B.A., Chemistry, UC Santa Cruz, Santa Cruz CA 1976

Internships

Internal Medicine, California-Pacific Medical Center, San Francisco CA 1984-1985

Residency

Internal Medicine, California-Pacific Medical Center, San Francisco CA 1985-1987

Fellowships

Nephrology, UC San Francisco, San Francisco CA 1991

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine, Nephrology

Professional Memberships

American Association for the Advancement of Science
American College of Physicians
American Society of Nephrology (ASN), Fellow

Honors and Awards

UC Davis Career Achievement Research Award, 2016
Medical Director, Western States Endurance Run (the world's first and premier ultramarathon),

Robert H. Weiss, M.S., M.D.

2013, 2014, 2015, 2016, 2017, 2018, 2019
Joan Oettinger Award for Outstanding Cancer Research, 2005
VA Medical Research Technologies Researcher spotlight, 2005
VA Research Honors, 2004

Select Recent Publications

Liu J, Yang DC, Zhang J, Hsu SW, Weiss RH, Chen CH. A Novel Renoprotective Strategy: Upregulation of PD-L1 Mitigates Cisplatin-Induced Acute Kidney Injury. Int J Mol Sci. 2021 Dec 10;22(24):13304. doi:10.3390/ijms222413304. PMID:34948109.

Høeg TB, Chmiel K, Warrick AE, Taylor SL, Weiss RH. Ultramarathon Plasma Metabolomics: Phosphatidylcholine Levels Associated with Running Performance. Sports (Basel). 2020 Apr 1;8(4): 44. doi:10.3390/sports8040044. PMID:32244618.

Asawa RR, Danchik C, Zahkarov A, Chen Y, Voss T, Jadhav A, Wallace DP, Trott JF, Weiss RH, Simeonov A, Martinez NJ. A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells. Sci Rep. 2020 Mar 6;10(1): 4203. doi:10.1038/s41598-020-61082-3. PMID:32144367.

Weiss RH. Introduction: Why Do We Need a Special Volume on Kidney Cancer? Semin Nephrol. 2020 Jan;40(1):1. doi:10.1016/j.semnephrol.2019.12.001. PMID:32130961.

Shenker BJ, Walker LM, Zekavat A, Weiss RH, Boesze-Battaglia K. The Cell-Cycle Regulatory Protein p21CIP1/WAF1 Is Required for Cytolethal Distending Toxin (Cdt)-Induced Apoptosis. Pathogens. 2020 Jan 2;9(1):38. doi:10.3390/pathogens9010038. PMID:31906446.

Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, Neil MO, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene. 2020 Feb;39(6):1231-1245. doi:10.1038/s41388-019-1059-0. Epub 2019 Oct 15. PMID:31616061.

Robert H. Weiss, M.S., M.D.

Xu J, Chang WH, Fong LWR, Weiss RH, Yu SL, Chen CH. Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma. Signal Transduct Target Ther. 2019;4:2. doi: 10.1038/s41392-019-0035-z. eCollection 2019. PMID:30701095.

Kim K, Trott JF, Gao G, Chapman A, Weiss RH. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. BMC Nephrol. 2019 Feb 25;20(1):66. doi:10.1186/s12882-019-1249-6. PMID:30803434.

Trott JF, Hwang VJ, Ishimaru T, Chmiel KJ, Zhou JX, Shim K, Stewart BJ, Mahjoub MR, Jen KY, Barupal DK, Li X, Weiss RH. Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1855-F1868. doi:10.1152/ajprenal.00025.2018. Epub 2018 Oct 3. PMID:30280600.

Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. Oncotarget. 2018 Oct 2;9(77):34567-34581. doi:10.18632/oncotarget.26179. PMID:30349650.

UCDAVIS
HEALTH